SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Art Vandelay AIA who wrote (3237)6/7/1999 6:00:00 PM
From: David Howe  Read Replies (2) | Respond to of 10280
 
IJ, Good question.

Art, Good answer. My estimates are in the same ballpark as yours.

On a different subject; IJ, please post your notes from today's conference on this board as well. The implications of several of Southwell's comments are very bullish. A review of these comments by this board would be helpful. Thanks.

Dave




To: Art Vandelay AIA who wrote (3237)6/7/1999 11:35:00 PM
From: GENE KRANE  Read Replies (2) | Respond to of 10280
 
Xopenex may not warrant a higher price or further marketing efforts by Sepracor; today (june 4, 1999) The Medical Letter, a prestigious medical newsletter, concluded that there is no significant advantage over albuterol. There was very little difference in side effects (ie., nervousness and heart rate increase)a major reason for making the "L" ISOMER, therefore can't command a high price unless proven otherwise .


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News